Medicines advice

Search Filters

Know what you're looking for?

Submission type

British National Formulary - Chapter

Pharmaceutical company

From

To

Advice

Accepted Not recommended Restricted Superseded Withdrawn Interim acceptance

Process

End of life/orphan Ultra orphan

Additional Details

Patient Access Scheme

Advanced Search

SMC ID	Date	Medicine	Submission Type	Indication
SMC2625	11/12/2023	degarelix (Firmagon)	Abbreviated	for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer
560/09	17/01/2011	degarelix (Firmagon)	Resubmission	for the treatment of adult male patients with advanced hormone-dependent prostate cancer.

No medicines have been found.